Literature DB >> 16810112

Range of normal neutrophil counts in healthy zimbabwean infants: implications for monitoring antiretroviral drug toxicity.

Jennifer Wells1, Avinash K Shetty, Lynda Stranix, Meira S Falkovitz-Halpern, Tsungai Chipato, Norbert Nyoni, Patrick Mateta, Yvonne Maldonado.   

Abstract

Mother-to-child HIV prevention trials in sub-Saharan Africa use the US National Institutes of Health Division of AIDS (DAIDS) grading scale to monitor hematologic toxicity. A recent study of nevirapine prophylaxis given for 6 months in breast-feeding Zimbabwean infants reported several cases of relative neutropenia in clinically well infants, raising concerns of drug toxicity. However, the DAIDS tables are based on normal blood counts for white infants, although there is evidence that black African infants may have lower absolute neutrophil counts (ANCs) than white infants. To establish normal hematologic values in black Zimbabwean infants and to quantify the apparent prevalence of relative neutropenia in this population, we evaluated HIV-uninfected healthy infants born to HIV-uninfected women at birth, 10 days, 6 weeks, 3, and 4 months of life. A physical examination and blood count were performed at each visit, and an HIV test was performed at the final visit. The ANC values were graded using the DAIDS table. A total of 145 healthy term infants satisfied the inclusion criteria. The mean ANC values for Zimbabwean infants were less than half of the corresponding standard values at all 5 time points (P < 0.0001). Using the DAIDS table in use at the time that the blood was collected, 57% of these healthy infants had relative neutropenia of any grade at birth, followed by 29% at day 10, 53% at 6 weeks, 32% at 3 months, and 37% at 4 months of life. Our data indicate that relative neutropenia exists in healthy black Zimbabwean infants. The guidelines for identifying toxicity were changed in December 2004. However, even by the new DAIDS tables, 43%, 23%, 24%, 42%, and 43% of these healthy babies had relative neutropenia at the time of the 5 visits. Future HIV prevention and treatment trials in sub-Saharan Africa should use normal hematologic values derived from African infants to avoid the overestimation of antiretroviral drug toxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16810112     DOI: 10.1097/01.qai.0000224975.45091.a5

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  16 in total

1.  Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi.

Authors:  Charles van der Horst; Charles Chasela; Yusuf Ahmed; Irving Hoffman; Mina Hosseinipour; Rodney Knight; Susan Fiscus; Michael Hudgens; Peter Kazembe; Margaret Bentley; Linda Adair; Ellen Piwoz; Francis Martinson; Ann Duerr; Athena Kourtis; A Edde Loeliger; Beth Tohill; Sascha Ellington; Denise Jamieson
Journal:  Contemp Clin Trials       Date:  2008-09-07       Impact factor: 2.226

2.  Hematologic and immunologic parameters in Zimbabwean infants: a case for using local reference intervals to monitor toxicities in clinical trials.

Authors:  Stephanie B Troy; Ali Rowhani-Rahbar; LauraLe Dyner; Georgina Musingwini; Avinash K Shetty; Godfrey Woelk; Lynda Stranix-Chibanda; Kusum Nathoo; Yvonne A Maldonado
Journal:  J Trop Pediatr       Date:  2011-04-18       Impact factor: 1.165

3.  Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated.

Authors:  Jim Aizire; Mary Glenn Fowler; Jing Wang; Avinash K Shetty; Lynda Stranix-Chibanda; Moreen Kamateeka; Elizabeth R Brown; Steve G Bolton; Philippa M Musoke; Hoosen Coovadia
Journal:  AIDS       Date:  2012-01-28       Impact factor: 4.177

4.  Considerations in using US-based laboratory toxicity tables to evaluate laboratory toxicities among healthy malawian and Ugandan infants.

Authors:  Irene R Lubega; Mary Glenn Fowler; Philippa M Musoke; Ali Elbireer; Danstan Bagenda; George Kafulafula; Jeanne Ko; Linda Mipando; Mike Mubiru; Newton Kumwenda; Taha Taha; J Brooks Jackson; Laura Guay
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

5.  Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled trial.

Authors:  Shahin Lockman; Michael Hughes; Kate Powis; Gbolahan Ajibola; Kara Bennett; Sikhulile Moyo; Erik van Widenfelt; Jean Leidner; Kenneth McIntosh; Loeto Mazhani; Joseph Makhema; Max Essex; Roger Shapiro
Journal:  Lancet Glob Health       Date:  2017-05       Impact factor: 26.763

6.  Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.

Authors:  Theodore D Ruel; Edward P Acosta; Jessica P Liu; Kathryn P Gray; Kathleen George; Nicole Montañez; Stephanie Popson; Ann M Buchanan; Mattie Bartlett; Dale Dayton; Patricia Anthony; Cynthia Brothers; Cynthia Vavro; Rajendra Singh; Lucy Koech; Tichaona Vhembo; Blandina T Mmbaga; Jorge A Pinto; Els F M Dobbels; Moherndran Archary; Kulkanya Chokephaibulkit; Pradthana Ounchanum; Jaime G Deville; Rohan Hazra; Ellen Townley; Andrew Wiznia
Journal:  Lancet HIV       Date:  2022-05       Impact factor: 16.070

7.  Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.

Authors:  Woong Hwan Bae; Carolyn Wester; Laura M Smeaton; Roger L Shapiro; Shahin Lockman; Kenneth Onyait; Ibou Thior; Max Essex
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

8.  Neutrophil count in African mothers and newborns and HIV transmission risk.

Authors:  Athena P Kourtis; Michael G Hudgens; Dumbani Kayira
Journal:  N Engl J Med       Date:  2012-12-06       Impact factor: 91.245

9.  Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.

Authors:  Theodore D Ruel; Edmund V Capparelli; Camlin Tierney; Bryan S Nelson; Anne Coletti; Yvonne Bryson; Mark F Cotton; Stephen A Spector; Mark Mirochnick; Rebecca LeBlanc; Christina Reding; Bonnie Zimmer; Deborah Persaud; Mutsa Bwakura-Dangarembizi; Kimesh L Naidoo; Rohan Hazra; Patrick Jean-Philippe; Ellen G Chadwick
Journal:  Lancet HIV       Date:  2020-11-23       Impact factor: 12.767

10.  Immunohaematological reference values for HIV-negative healthy adults in Botswana.

Authors:  Madisa Mine; Sikhulile Moyo; Penny Stevens; Kurt Michael; Vladimir Novitsky; Kgomotso Makhaola; Aida Asmelash; S'khatele Molefhabangwe; Elias Woldegabriel; Gaseboloke Mothowaeng; Talkmore Maruta; Charity Kamhukamwe; Phibeon M Mangwendeza; Molly Holmes-Pretorius; Isaac Mtoni; Modisa Motswaledi; Rosemary Musonda; Ndwapi Ndwapi; Joseph Makhema; Richard Marlink; Khumo Seipone; Tendani Gaolathe; Max Essex
Journal:  Afr J Lab Med       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.